Aurinia Pharmaceuticals reported quarterly EPS of $0.25, beating the Zacks Consensus Estimate of $0.18 by $0.07, or about 39%. Earnings also improved from $0.16 per share a year ago, indicating year-over-year growth in profitability. The headline is modestly positive and could support the stock, but the article contains no revenue or guidance details.
Aurinia Pharmaceuticals reported quarterly EPS of $0.25, beating the Zacks Consensus Estimate of $0.18 by $0.07, or about 39%. Earnings also improved from $0.16 per share a year ago, indicating year-over-year growth in profitability. The headline is modestly positive and could support the stock, but the article contains no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
